Somatostatin in diabetic retinopathy.
Diabetic retinopathy is a leading cause of legal blindness in the adult population (30-70 year olds). The anatomical changes that occur in the retina during the course of disease are well defined in the literature but the causes are not yet fully understood. Laser photocoagulation of the retina and vitrectomy are currently used to treat diabetic retinopathy but the procedures are invasive and provide only temporary protection. The use of long-acting analogues of the naturally occurring peptide, somatostatin, has been considered by some a promising therapeutic option for retinopathy over the last decade. Experimental evidence supports its use in diabetic retinopathy but further clinical evidence, from larger treatment groups of longer trial duration, is required. Improved analogues with increased selectivity and modified bi-specific analogues are currently emerging and may help to make the use of somatostatin analogues a more realistic option in the treatment of diabetic retinopathy.
Croxen
R
R
Department of Internal Medicine (Laboratorium Inwendige Geneeskunde), Erasmus MC Rotterdam, The Netherlands. r.croxen@wanadoo.nl
Baarsma
G S
GS
Kuijpers
R W A M
RW
van Hagen
P M
PM
D000818:Animals; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives*; D016896:Treatment Outcome
D013004:Somatostatin; D015282:Octreotide